OPKO Health (NASDAQ:OPK) Upgraded by StockNews.com to "Hold" Rating

OPKO Health (NASDAQ:OPK - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Tuesday.

Several other research firms have also commented on OPK. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th. Piper Sandler reiterated an "overweight" rating and set a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, Barrington Research restated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Stock Performance

Shares of OPKO Health stock traded up $0.06 during trading on Tuesday, hitting $1.51. 2,546,751 shares of the company's stock traded hands, compared to its average volume of 3,042,016. OPKO Health has a 1 year low of $0.86 and a 1 year high of $1.76. The business has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $1.50. The stock has a market capitalization of $1.03 billion, a P/E ratio of -7.95 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the business's stock in a transaction on Friday, December 13th. The shares were bought at an average price of $1.59 per share, with a total value of $198,750.00. Following the transaction, the chief executive officer now directly owns 212,536,477 shares of the company's stock, valued at $337,932,998.43. The trade was a 0.06 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders bought 1,304,255 shares of company stock worth $2,024,605. 47.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OPKO Health

A number of institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP grew its holdings in OPKO Health by 800.0% during the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company's stock worth $55,528,000 after acquiring an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd purchased a new position in OPKO Health during the second quarter valued at approximately $1,840,000. Assenagon Asset Management S.A. raised its stake in OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company's stock worth $2,227,000 after buying an additional 876,272 shares in the last quarter. Clearline Capital LP purchased a new stake in OPKO Health during the third quarter worth $1,083,000. Finally, Squarepoint Ops LLC bought a new stake in OPKO Health during the 2nd quarter valued at $592,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.